^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDKN2A mutation

    i
    Entrez ID:
    1029
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) (NCT06222203)
    Phase N/A
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    06/17/2024
    Initiation :
    06/20/2024
    Primary completion :
    12/31/2034
    Completion :
    12/31/2035
    CDKN2A • CDKN2B
    |
    CDKN2A mutation
    Pancreatic Cancer Early Detection Program (PCEDP) (NCT02206360)
    Phase N/A
    White Plains Hospital
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2024
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (NCT05529069)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    01/25/2023
    Primary completion :
    04/28/2027
    Completion :
    04/28/2027
    TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals (NCT03250078)
    Phase N/A
    Nuvance Health
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    11/01/2016
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation
    Pancreatic Cancer Screening for At-risk Individuals (PancreasScan) (NCT05006131)
    Phase N/A
    Beth Israel Deaconess Medical Center
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/10/2020
    Primary completion :
    03/10/2027
    Completion :
    03/10/2028
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
    Melanoma Detection in Switzerland With VECTRA (MELVEC) (NCT04605822)
    Phase N/A
    University Hospital, Basel, Switzerland
    Completed
    Last update posted :
    03/19/2024
    Initiation :
    01/25/2021
    Primary completion :
    01/31/2024
    Completion :
    01/31/2024
    CDKN2A
    |
    CDKN2A mutation
    Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) (NCT02546661)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/03/2016
    Primary completion :
    03/18/2020
    Completion :
    06/28/2024
    HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    Pancreas Registry and High Risk Registry (NCT02775461)
    Phase N/A
    Icahn School of Medicine at Mount Sinai
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    03/01/2013
    Primary completion :
    11/01/2033
    Completion :
    11/01/2033
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MSH2
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation
    Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) (NCT03242382)
    Phase 2
    Grupo Espanol de Investigacion en Sarcomas
    Recruiting
    Last update posted :
    01/23/2024
    Initiation :
    03/31/2017
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    CDKN2A • CDK4
    |
    CDKN2A mutation • CDK4 overexpression
    |
    Ibrance (palbociclib)
    MoleGazer Development Feasibility Study (NCT05015816)
    Phase N/A
    Oxford University Hospitals NHS Trust
    Recruiting
    Last update posted :
    12/18/2023
    Initiation :
    09/13/2021
    Primary completion :
    02/28/2024
    Completion :
    02/12/2026
    CDKN2A • CDK4
    |
    CDKN2A mutation • CDK4 mutation
    Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer (NCT05013216)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    09/04/2023
    Initiation :
    04/11/2022
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1
    |
    KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation
    |
    Hiltonol (poly-ICLC) • KRAS peptide vaccine
    Dasatinib and Crizotinib in Advanced Cancer (NCT01744652)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    06/07/2023
    Initiation :
    03/01/2013
    Primary completion :
    03/01/2019
    Completion :
    03/01/2019
    BRAF • ALK • MET • CDKN2A • DDR2 • CTGF
    |
    BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification
    |
    Xalkori (crizotinib) • dasatinib
    The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals (NCT05740111)
    Phase N/A
    Oslo University Hospital
    Enrolling by invitation
    Last update posted :
    02/22/2023
    Initiation :
    09/01/2022
    Primary completion :
    12/31/2042
    Completion :
    12/31/2042
    TP53 • STK11 • CDKN2A • PRSS1
    |
    TP53 mutation • STK11 mutation • CDKN2A mutation
    A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (NCT03965845)
    Phase 1b/2
    Calithera Biosciences, Inc
    Completed
    Last update posted :
    09/19/2022
    Initiation :
    06/25/2019
    Primary completion :
    09/24/2021
    Completion :
    09/24/2021
    KRAS • CDKN2A
    |
    KRAS mutation • KRAS wild-type • CDKN2A mutation
    |
    Ibrance (palbociclib) • telaglenastat (CB-839)
    Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer. (TCOG) (NCT03174574)
    Phase N/A
    Mayo Clinic
    Completed
    Last update posted :
    06/16/2022
    Initiation :
    08/17/2016
    Primary completion :
    01/25/2019
    Completion :
    01/25/2019
    CDKN2A
    |
    CDKN2A mutation
    LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) (NCT02187783)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    07/18/2019
    Initiation :
    08/25/2014
    Primary completion :
    01/17/2018
    Completion :
    01/17/2018
    CDKN2A • CCND1 • CDK4 • CDK6 • CCND3
    |
    CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification
    |
    Kisqali (ribociclib)
    Family Lifestyle Actions and Risk Education Study (NCT02846714)
    Phase N/A
    University of Utah
    Completed
    Last update posted :
    05/08/2019
    Initiation :
    07/01/2016
    Primary completion :
    11/01/2017
    Completion :
    11/01/2017
    CDKN2A
    |
    CDKN2A mutation
    Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery (NCT02540876)
    Phase 1
    University of Chicago
    Completed
    Last update posted :
    04/22/2019
    Initiation :
    09/08/2015
    Primary completion :
    02/08/2019
    Completion :
    02/08/2019
    CDKN2A
    |
    CDKN2A deletion • CDKN2A mutation
    |
    ilorasertib (ABT348)
    Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study) (NCT00714701)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    09/07/2018
    Initiation :
    06/01/2008
    Primary completion :
    07/01/2016
    Completion :
    07/01/2016
    BRCA1 • BRCA2 • STK11 • CDKN2A
    |
    STK11 mutation • PALB2 mutation • CDKN2A mutation